Research Paper Volume 15, Issue 20 pp 11244—11267
CDKN2A was a cuproptosis-related gene in regulating chemotherapy resistance by the MAGE-A family in breast cancer: based on artificial intelligence (AI)-constructed pan-cancer risk model
Figure 3. Expression distribution and prognosis hazard of CRGs in pan-cancer. (A) CDKN2A has prognostic significance in 6 types of cancer; DLAT in 10 types of cancer; DLD in 6 types of cancer; FDX1 in KIRC and LGG; GLS in 4 types of cancer; LIAS in 5 types of cancer; LIPT1 in 9 types of cancer; MTF1 in 3 types of cancer; PDHB1 in 7 types of cancer; LIAS in 5 types of cancer; PDHB in 5 types of cancer. (B) Differential expression of FDX1 in 7 types of cancer; LISA in DLBC and THYM; LIPT1 in DLBC, GBM, and THYM; DLD in 5 types of cancer; GLS in 16 types of cancer; DLAT in 6 types of cancer; PDHB in DLBC, KIRC, PAAD, and THYM; PDHA1 in DLBC, KIRC, LAML, and THYM; MTF1 in CHOL, LAML, and TGCT; CDKN2A in 27 types of cancer.